Title: Evaluation of talazoparib, a PARP inhibitor, in patients with somatic BRCA mutant metastatic breast cancer: Genotyping based clinical trial
Principal Investigator: Neelima Vidula, MD, of Massachusetts General Hospital in Boston
Description: Researchers are conducting a phase 2 study to determine the safety and efficacy of talazoparib for patients with BRCA1/2-mutated metastatic breast cancer.
Continue Reading
Patients will receive talazoparib orally each day.
The primary outcome is progression-free survival. Secondary outcomes include objective response rate and treatment-related serious adverse events.
To be eligible for this study, patients must be 18 years of age or older. They must have metastatic breast cancer with deleterious somatic BRCA1/2 mutations, as detected by a CLIA-certified clinical assay. For a complete list of eligibility criteria, please see the reference.
Status: Recruiting
This study is sponsored by Massachusetts General Hospital in collaboration with Pfizer.
Reference
ClinicalTrials.gov. Evaluation of talazoparib, a PARP inhibitor, in patients with somatic BRCA mutant metastatic breast cancer: Genotyping based clinical trial. NCT03990896. Accessed September 19, 2022.
